Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
127 hedge funds and large institutions have $360M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 47 increasing their positions, 36 reducing their positions, and 19 closing their positions.
73% more call options, than puts
Call options by funds: $5.19M | Put options by funds: $3M
31% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 36
5% more capital invested
Capital invested by funds: $344M → $360M (+$16.9M)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
2% less funds holding
Funds holding: 129 → 127 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Twin Securities
New York
|
+$8.81M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$3.95M |
| 3 |
MCM
Moore Capital Management
New York
|
+$2.68M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.51M |
| 5 |
Renaissance Technologies
New York
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.66M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.86M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$3.57M |
| 4 |
PC
PointState Capital
New York
|
-$3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.59M |
SGYP Hedge Fund Activity: Q4 2015 in Review
127 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q4 2015, worth a combined $360M — up 4.9% from $344M a quarter earlier.
Fund positioning in SGYP was balanced in Q4 2015: 19 funds opened new positions, 19 closed out, 47 added to existing stakes and 36 trimmed.
The largest buyer was Twin Securities, opening a new position worth an estimated $8.81M. The largest seller was Citadel Advisors, cutting an estimated $8.66M.
- 127 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q4 2015, down from 129 in Q3 2015.
- Funds reported $360M of Synergy Pharmaceuticals, Inc Common Stock stock for Q4 2015, up 4.9% quarter-over-quarter.
- 19 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q4 2015 and 19 closed out, a net change of 0 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q4 2015 was Twin Securities, an estimated $8.81M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q4 2015 was Citadel Advisors, an estimated $8.66M sold.
Based on aggregated 13F filings for Q4 2015.